Drug firm Lupin Wednesday said inspection by the US health regulator of its bioresearch centre in Pune has been completed without any observations.
"This is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility," Lupin said in a statement.
The inspection of Lupin Bioresearch Centre by the United States Food and Drug Administration (USFDA) has been successfully completed without any observations, it added.
Commenting on the development, Lupin MD Nilesh Gupta said: "Such a high level of compliance reiterates Lupin's commitment to high-quality standards across its world class research centres."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app